Accueil Ernstrade Bourse Actualite Stock


Agenix Limited is engaged in the development of ThromboView project, a product in development related to the detection of blood clots. Its lead product, ThromboView, is an internally developed, humanised monoclonal antibody based imaging technology that detects live blood clots in the human body. The Company’s lead indicator, ThromboView uses radiolabelled antibodies, which bind to a biomarker to locate active blood clots in the body. It also engaged in the development of the operations of Shanghai Rui Guang Bio-Pharma Development Co Limited (SHRG) in respect of expanding a pipeline of anti-viral drugs for international distribution. The Company operates in three segments: Agenix (Shanghai) Biopharmaceuticals, Monoclonal antibody product development and Molecular biology.
11 Durbell Street
Acacia Ridge, QLD 4110
+61-7-33706396 (Phone)
+61-7-33706347 (Fax)          

Copyright  2011